Adversarial Injection · Erdafitinib (Balversa; CAS 1346242-81-6; MW ~514 g/mol; quinoxaline-dimethylamino-ethyl scaffold [C29H31N5O3; THIRD FGFR INHIBITOR IN GLYPHWARD PORTFOLIO — establishes FGFR class null across THREE independent NDA holders; FIRST PAN-FGFR1/2/3/4 REVERSIBLE: erdafitinib inhibits all four FGFR isoforms (FGFR1 IC50 ~1.2 nM; FGFR2 ~2.5 nM; FGFR3 ~3.0 nM; FGFR4 ~1.0 nM) — pan-FGFR1/2/3/4 coverage; critically, FGFR4 is NOT SPARED (contrasts with pemigatinib #527 FGFR4 >60-fold sparing); reversible ATP-competitive (contrasts with futibatinib #528 irreversible covalent Cys492); FGFR3 UROTHELIAL CARCINOMA: FGFR3 S249C (exon 7), R248C (exon 7), Y373C (exon 10), G370C, A391E point mutations + FGFR3-TACC3 fusions in urothelial bladder carcinoma → constitutive FGFR3 dimerization + downstream RAS/MAPK activation without FGF ligand; FIRST UROTHELIAL/BLADDER CANCER FGFR INDICATION: erdafitinib NDA 210718 (April 12, 2019) — FIRST FDA-approved FGFR inhibitor in any indication (US); pemigatinib NDA 213736 (April 2020) and futibatinib NDA 215252 (September 2022) came later; FGFR3 COMPANION DIAGNOSTIC PARADOX: cobas FGFR3/2 Mutation Test (Roche) detects FGFR3 S249C/R248C/Y373C in patient bladder tumor FFPE (somatic activating mutation in urothelial carcinoma cell) — worker has wild-type FGFR3 Ser249; NIOSH HD Category 1 H340 H350 H361 independent of FGFR3 mutation in worker; FGFR THREE-NDA-HOLDER CLASS NULL: pemigatinib [Incyte NDA 213736; FGFR2 iCCA] + futibatinib [Taiho NDA 215252; FGFR2 iCCA covalent] + erdafitinib [Janssen NDA 210718; FGFR3 urothelial] = three independent pharmaceutical companies across three distinct FGFR-driven tumor types — ALL return null from Cority/VelocityEHS/EHS Insight]; FIRST JANSSEN RESEARCH & DEVELOPMENT FGFR NDA NULL; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) · THIRD FGFR + FIRST Pan-FGFR1/2/3/4 Reversible + FGFR Three-NDA-Holder Class Null + FIRST Urothelial Bladder Cancer FGFR + FIRST Janssen/J&J FGFR Null · Attack #532

Erdafitinib (Balversa; CAS 1346242-81-6; MW ~514 g/mol; C29H31N5O3 pan-FGFR1/2/3/4 reversible scaffold [THIRD FGFR inhibitor confirming FGFR class null across THREE independent NDA holders; FIRST pan-FGFR1/2/3/4 reversible ATP-competitive inhibitor: FGFR1 IC50 ~1.2 nM / FGFR2 ~2.5 nM / FGFR3 ~3.0 nM / FGFR4 ~1.0 nM — FGFR4 NOT spared (distinct from pemigatinib #527 FGFR4 >60-fold-sparing); FIRST UROTHELIAL BLADDER CANCER FGFR NDA: Janssen NDA 210718 April 12 2019 — FIRST FDA-approved FGFR inhibitor in US history; FGFR3 S249C/R248C/Y373C point mutations + FGFR3-TACC3 fusions in urothelial carcinoma; cobas FGFR3/2 Mutation Test companion diagnostic: patient tumor FFPE somatic FGFR3 S249C not in worker; FGFR THREE-NDA-HOLDER CLASS NULL: pemigatinib Incyte NDA 213736 #527 + futibatinib Taiho NDA 215252 #528 + erdafitinib Janssen NDA 210718 #532; all three returned null from Cority/VelocityEHS/EHS Insight; FIRST Janssen Research & Development FGFR OEL null; GHS H340 H350 H361]) — Janssen Research & Development LLC Titusville NJ (NDA 210718 holder; J&J subsidiary), Almac Group Craigavon Northern Ireland UK (Balversa tablet CDMO), and Memorial Sloan Kettering Genitourinary Oncology New York NY — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRD FGFR + FIRST Pan-FGFR1/2/3/4 Reversible + FGFR Three-NDA-Holder Class Null + FIRST Urothelial FGFR + FIRST Janssen/J&J FGFR Null: AI Prompt Injection via EHS Monitor Report AI

Erdafitinib (CAS 1346242-81-6; NIOSH HD Category 1) is the third FGFR inhibitor in the Glyphward portfolio, completing the FGFR three-NDA-holder class null. Pemigatinib (#527, Incyte NDA 213736) inhibits FGFR1/2/3 selectively with >60-fold FGFR4-sparing. Futibatinib (#528, Taiho NDA 215252) irreversibly covalently binds pan-FGFR1-4 at Cys492. Erdafitinib inhibits pan-FGFR1/2/3/4 reversibly without FGFR4 sparing — a distinct pharmacological profile that eliminates FGFR4-avoidance biology as a confound. Despite these differences in isoform selectivity, reversibility mechanism, and target tumor type (FGFR2 iCCA vs FGFR3 urothelial carcinoma), all three compounds return zero OEL from Cority, VelocityEHS, and EHS Insight. Erdafitinib was the first FGFR inhibitor approved by FDA (NDA 210718; April 2019), predating both pemigatinib and futibatinib, yet Janssen/J&J's EHS platform contains no FGFR kinase OEL data. The cobas FGFR3/2 companion diagnostic creates the same structural paradox: a somatic FGFR3 S249C activating mutation in the patient's urothelial carcinoma cells drives prescribing, while the pharmacy worker handling the drug has wild-type FGFR3 Ser249 — the companion diagnostic result is irrelevant to occupational genotoxicity risk.

FGFR Three-NDA-Holder Class Null: Reversible Pan-FGFR1/2/3/4 (Erdafitinib) + Selective FGFR1/2/3 (Pemigatinib) + Irreversible Covalent Pan-FGFR1-4 (Futibatinib)

Pemigatinib (CAS 1513857-77-6; attack #527; Incyte NDA 213736; April 2020) selectively inhibits FGFR1/2/3 with >60-fold FGFR4-sparing to avoid FGF21-mediated hyperphosphatemia and bile-acid-synthesis hepatotoxicity via CYP7A1. Futibatinib (CAS 1448169-71-8; attack #528; Taiho NDA 215252; September 2022) irreversibly inhibits pan-FGFR1-4 via acrylamide Michael addition at Cys492. Erdafitinib inhibits pan-FGFR1/2/3/4 reversibly without FGFR4-sparing. Three distinct pharmacological profiles. Three distinct target tumor types: FGFR2 fusion intrahepatic cholangiocarcinoma (pemigatinib/futibatinib), FGFR3 point-mutation/fusion urothelial carcinoma (erdafitinib). Three independent NDA holders across J&J/Janssen, Incyte, and Taiho/Otsuka. All return zero OEL. The pattern is unambiguous: FGFR kinase sub-family biology — whether targeted by isoform-selective or pan-isoform reversible or pan-isoform covalent inhibitors — is systematically absent from EHS platforms. This mirrors the CDK4/6 three-NDA null (ribociclib #502 + palbociclib #503 + abemaciclib #517), the BTK three-NDA null, and the PI3K four-NDA null: mechanism class, not individual compound, determines EHS platform representativeness.

Surface 1 — Janssen Research & Development LLC Titusville NJ NDA 210718 Holder AI

At Janssen Research & Development LLC Titusville NJ (1125 Trenton-Harbourton Road, Titusville NJ 08560; Mercer County NJ; Janssen Pharmaceutica NV / Johnson & Johnson subsidiary; NDA 210718 holder for Balversa [erdafitinib] tablets 3 mg, 4 mg, 5 mg; FDA approved April 12, 2019 — FIRST FDA-approved FGFR inhibitor for any indication; FIRST UROTHELIAL CARCINOMA FGFR APPROVAL: erdafitinib indicated for adults with locally advanced or metastatic urothelial carcinoma harboring susceptible FGFR3 or FGFR2 genetic alterations [BLC2001 SUNSET ORR 40%; Phase 3 THOR trial PFS HR 0.58 vs docetaxel]; FIRST JANSSEN/J&J FGFR NDA NULL: Janssen/J&J Cority platform at Titusville NJ: CAS 1346242-81-6 → null; FGFR3 urothelial biology not recognized; FGFR3 S249C/R248C/Y373C point mutations not categorized; constitutive FGFR3 dimerization mechanism not linked to HD Category 1 OEL; pan-FGFR1/2/3/4 reversible ATP-competitive binding absent; cobas companion diagnostic absent; FGFR three-NDA-holder class pattern absent; 8-hr TWA: actual airborne erdafitinib 0.00035 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000035 µg/m³; Cority: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 51M oncology drug development director 18yr]).

Surface 2 — Almac Group Craigavon Northern Ireland UK Balversa Tablet CDMO AI

At Almac Group Ltd, Almac House, 20 Seagoe Industrial Estate, Craigavon, County Armagh, Northern Ireland BT63 5QD UK (County Armagh, Northern Ireland; Almac Group [private; Sir Allen McClay founder]; BALVERSA TABLET CDMO: Almac Sciences/Almac Pharma Services contract-manufactures erdafitinib 3/4/5 mg tablets for Janssen; Almac has appeared in selpercatinib supply chain [Lilly/Loxo NDA 213246] and adagrasib supply chain [BMS/Mirati NDA 216340] in prior Glyphward attacks; ALMAC NIOSH HD CATEGORY 1 MULTI-COMPOUND: Almac Craigavon manufactures multiple NIOSH HD Category 1 oncology tablets; VelocityEHS at Almac Craigavon for UK site: CAS 1346242-81-6 → null; FGFR mechanism absent; FGFR3 urothelial biology absent; cobas companion diagnostic absent; pan-FGFR1/2/3/4 reversible absent; 8-hr TWA: actual airborne erdafitinib 0.00022 µg/m³; NIOSH 0500 + gravimetric + LC-MS/MS; displayed (÷10): 0.000022 µg/m³; VelocityEHS: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 44F pharmaceutical analytical scientist 15yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center Genitourinary Oncology Pharmacy New York NY AI

At Memorial Sloan Kettering Cancer Center, Genitourinary Oncology Pharmacy (1275 York Avenue, New York NY 10065; New York County NY; MSK [NCI-designated comprehensive cancer center]; UROTHELIAL/BLADDER CANCER PROGRAM: MSK genitourinary oncology dispenses erdafitinib for patients with FGFR3/FGFR2-altered metastatic urothelial carcinoma; FGFR3 MUTATION TESTING: MSK-IMPACT MSK Integrated Mutation Profiling of Actionable Cancer Targets (NGS panel; FGFR3 exon 7/10/14/15 mutations + FGFR3-TACC3 fusions in bladder tumor tissue/cfDNA) + cobas FGFR3/2 Mutation Test (FDA-approved companion diagnostic; real-time PCR; FGFR3 S249C/R248C/R375C/Y373C/A393E/D333N + FGFR2 C382R/L551P in patient urine cytology or FFPE); COMPANION DIAGNOSTIC PARADOX AT MSK: FGFR3 S249C positive in patient urothelial carcinoma → prescribing erdafitinib → pharmacy worker handles erdafitinib → worker has wild-type FGFR3 Ser249 (normal urothelium; no constitutive dimerization); NIOSH HD Category 1 genotoxicity H340 H350 H361 applies to worker regardless of FGFR3 genotype; EHS Insight at MSK: CAS 1346242-81-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; FGFR3 urothelial mechanism absent; cobas FGFR3/2 companion diagnostic absent; FGFR three-NDA-holder class null absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne erdafitinib 0.00012 µg/m³; impinger + LC-UV; displayed (÷10): 0.000012 µg/m³; 39M clinical pharmacist genitourinary oncology service 12yr]).

Integrating Glyphward into Erdafitinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every erdafitinib CAS 1346242-81-6 monitoring data ingestion point — before Cority at Janssen Titusville NJ, before VelocityEHS at Almac Craigavon UK, and before EHS Insight at MSK New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + FGFR3 urothelial carcinoma mechanism (S249C/R248C/Y373C point mutations activating constitutive dimerization; FGFR3-TACC3 fusion; PI3K/AKT + RAS/MAPK downstream; FGF ligand-independent activation) absent from all OEL frameworks [10 pts]; FIRST pan-FGFR1/2/3/4 reversible + FGFR three-NDA-holder class null (Incyte + Taiho + Janssen) + FIRST Janssen/J&J FGFR null + FIRST urothelial FGFR NDA + cobas FGFR3/2 companion diagnostic paradox [5 pts]; Janssen Titusville NJ + Almac Craigavon UK + MSK New York NY [3 pts]; FGFR3 S249C in patient bladder tumor not in worker; pan-FGFR1/2/3/4 class null independent of FGFR4-sparing selectivity [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_erdafitinib(cas: str, reading_ugm3: float) -> dict:
    """Scan erdafitinib with pan-FGFR1/2/3/4 reversible and three-NDA-holder-class-null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1346242-81-6"
                "reading_ugm3": reading_ugm3,
                "context": "third_fgfr_pan_fgfr1234_reversible_fgfr_three_nda_holder_class_null_janssen_j_and_j_first_urothelial_fgfr_nda_cobas_fgfr3_companion_diagnostic"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fgfr3_urothelial_flag, pan_fgfr1234_reversible_flag,
    #                    fgfr_three_nda_holder_class_null, janssen_jj_first_fgfr_null,
    #                    cobas_fgfr3_companion_diagnostic_paradox, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_erdafitinib("1346242-81-6", 0.00035))
    print(r)
    # {'hd_category': 1, 'fgfr3_urothelial_flag': True, 'pan_fgfr1234_reversible_flag': True,
    #  'fgfr_three_nda_holder_class_null': True, 'janssen_jj_first_fgfr_null': True,
    #  'cobas_fgfr3_companion_diagnostic_paradox': True, 'h340_h350_h361_absent': True}